Video

BOLERO-2: Overcoming Treatment Resistance in Breast Cancer

Publish date: January 6, 2012

 

SAN ANTONIO – Dr. Howard Burris, Dr. William J. Gradishar, and Dr. Hope Rugo discuss the implications of the BOLERO-2 trial, which coupled everolimus with exemestane in women with advanced hormone resistant, estrogen receptor-positive breast cancer.

Recommended Reading

Less Trastuzumab Cardiotoxicity in Beta-Blocker Users
MDedge Hematology and Oncology
Pegfilgrastim Costly, Unnecessary in Some Breast Cancer Patients
MDedge Hematology and Oncology
Adjuvant Ibandronate: No Gain in Early Breast Cancer
MDedge Hematology and Oncology
Program Curbs Shoulder Morbidity Post Breast Cancer
MDedge Hematology and Oncology
Cancer Death Rates Continue to Drop
MDedge Hematology and Oncology
Do Bisphosphonates Reduce Cancer Risks?
MDedge Hematology and Oncology
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
MDedge Hematology and Oncology
Bisphosphonates as Antitumor Agents in Breast Cancer
MDedge Hematology and Oncology
Assay for Ductal Carcinoma In Situ
MDedge Hematology and Oncology
Retrospective Study of Patients with Metastatic Triple-Negative Breast Cancer: Survival, Health Care Utilization, and Cost
MDedge Hematology and Oncology